Pure class III antiarrhythmic drugs: focus on dofetilide.
Doshi
S K
SK
Veterans Administration Greater Los Angeles Health Care System, CA 90073, USA. skdoshi@ucla.edu
Singh
B N
BN
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004195:Disease Models, Animal; D004285:Dogs; D004594:Electrophysiology; D006333:Heart Failure / Q000150:complications; D006801:Humans; D010627:Phenethylamines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D013449:Sulfonamides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; D010627:Phenethylamines; D013449:Sulfonamides; C063533:dofetilide